<DOC>
	<DOCNO>NCT02582203</DOCNO>
	<brief_summary>The propose study prospective , open-label , randomize , multi-center trial ceftaroline versus vancomycin treatment ABSSSI patient document risk MRSA . Patients admit Detroit Medical Center , Henry Ford Hospital , St. John Medical Center Detroit Michigan document ABSSSI April 2012 November 2015 evaluate inclusion . Patients must present least 3 follow local signs/symptoms : pain , tenderness , swell erythema , warmth , drainage/discharge , induration , lymph node swelling/tenderness . Patients randomize 1:1 ceftaroline vancomycin optional anaerobic and/or Gram-negative coverage . The assignment study drug follow randomize list previously generate via computerized random mix block generator ( nQuery AdvisorÂ® 7.0 ) available study site . Patients randomized ceftaroline intravenously 600 mg infuse 1 hour every 12 hour patient normal renal function . Patients randomized vancomycin receive standard 15 mg/kg dose base total body weight infused 1 hour q 12 hour , dose interval adjust base creatinine clearance via institution-specific pharmacy protocol target serum trough concentration 10-20 mg/L within first 72 hour . Outcomes measure Clinically Evaluable patient population include day two three size reduction ( percentage ) clinical response end therapy discharge .</brief_summary>
	<brief_title>Clinical Economic Outcomes Ceftaroline Fosamil ABSSSI Documented Risk MRSA</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Skin Diseases</mesh_term>
	<mesh_term>Skin Diseases , Infectious</mesh_term>
	<mesh_term>Staphylococcal Skin Infections</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<mesh_term>Methicillin</mesh_term>
	<criteria>Acute bacterial skin skin structure infection ( cellulitis , major abscess , surgical site infection ) Presence MRSA document risk factor MRSA ( prior antibiotic use 60 day , prior hospital exposure 180 day , skin ulcer , central venous catheter ) Anticipating less two day hospital admission Signed informed consent Gas gangrene/progressive necrotizing infection Osteomyelitis Infections due Gramnegative pathogen Grampositive pathogen S. aureus Streptococcus present Pathogens known study entry resistant ceftaroline vancomycin Anticipated require nonstudy antibiotic active S. aureus another reason Treatment current episode ABSSSI &gt; 24 hour another intravenous antiMRSA antibiotic Surgical ( I &amp; D ) definitive/curative treatment Presence prosthetic hardware invasive device suspect source infection remove Life expectancy &lt; 2 month Open burn wound &gt; 30 % total body surface area Pregnant nursing mother Known allergic reaction vancomycin ceftaroline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Ceftaroline fosamil</keyword>
	<keyword>Vancomycin</keyword>
	<keyword>Acute bacterial skin skin structure infection</keyword>
	<keyword>Methicillin-resistant S. aureus</keyword>
</DOC>